Rigel Pharmaceuticals, Inc.

Greetings and welcome to the Rigel Pharmaceuticals Financial Conference Call for the second quarter of 2023. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Fury, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Fury. You may begin.

Welcome to our second quarter 2023 financial results and business update conference call. The financial press release for the second quarter 2023 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31st, 2022, and the subsequent filings with the SEC including our second quarter quarterly report on Form 10Q on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. At this time, I would like to turn the call over to Raul, to our President and Chief Executive Raul Rodriguez-Raul.

Thank you, Ray, and thank you everyone for joining today. Also with me today are Dave Santos, our chief commercial officer, and Dean Shorno, our chief financial officer. I'll be getting on slide four. We are pleased with the progress we've made in the first half of 2023 as we continue to build our hematology oncology company with our commercially available products and our development programs. In the second quarter, we continue to see year-over-year growth in demand for our first approved product, Tavalis, for adult chronic ITP. We're also pleased with the progress that we've made on the launch of our second approved product, Reslydia, for adult relapsal refractory IDH-positive AML. As we navigate the launch, the core focus of our commercial and medical affairs team has been driving awareness for Reslydia and establishing relationships with new doctors. A few key highlights on these initiatives from the quarter include robust engagement with the medical community at the 2023 ASCO Annual Meeting, the presentation of promising data in the post-venetoclast treated patients at the European Hematology Association 2023 Congress, and a second publication in Blood Advances, examining the preclinical and clinical development of res lydia and its role in the treatment landscape. These are important data that we recently published and presented. Dave will touch on these items a little bit later in this presentation. Looking at our development and expansion initiatives, we've made progress in the enrollment of our Phase 1b study of R289, our IRAC1 and IV inhibitor in lower risk MDS. And we are evaluating opportunities to expand our hematology oncology business further with clinical development for our already approved products into new indications. Additionally, our RIP-K1 program has advanced with our partner, Eli Lilly, and continues to progress with the initiation of a Phase 2A trial in patients with rheumatoid arthritis in the second quarter of 2023. I will provide further updates on our progress and strategies for these efforts later on in today's presentations. With that, I'll turn the call over to Dave for an overview of the quarter. To you, Dave. Thank you, Raoul.